PhaseBio Pharmaceuticals Inc

2019 Q1 Form 10-Q Financial Statement

#000156459019017982 Filed on May 09, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2018 Q1

Balance Sheet

Concept 2019 Q1 2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $51.90M
YoY Change
Cash & Equivalents $51.91M $10.77M
Short-Term Investments
Other Short-Term Assets $1.500M
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables $670.0K
Total Short-Term Assets $54.08M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $380.0K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $32.00K
YoY Change
Total Long-Term Assets $2.311M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $54.08M
Total Long-Term Assets $2.311M
Total Assets $56.39M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.100M
YoY Change
Accrued Expenses $1.300M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $400.0K
YoY Change
Total Short-Term Liabilities $3.800M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $6.841M
YoY Change
Other Long-Term Liabilities $1.700M
YoY Change
Total Long-Term Liabilities $6.841M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.800M
Total Long-Term Liabilities $6.841M
Total Liabilities $12.30M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$130.2M
YoY Change
Common Stock $25.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $24.00K
YoY Change
Treasury Stock Shares $29.97K
Shareholders Equity $44.08M -$101.7M
YoY Change
Total Liabilities & Shareholders Equity $56.39M
YoY Change

Cashflow Statement

Concept 2019 Q1 2018 Q1

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
20000
CY2018Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
20000
CY2019Q1 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
670000
CY2018Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
233000
CY2019Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1491000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1344000
CY2019Q1 us-gaap Assets Current
AssetsCurrent
54075000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
62628000
CY2019Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
380000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
355000
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1899000
CY2019Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
32000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
43000
CY2019Q1 us-gaap Assets
Assets
56386000
CY2018Q4 us-gaap Assets
Assets
63026000
CY2019Q1 phas Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
1316000
CY2018Q4 phas Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
2771000
CY2019Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
6841000
CY2018Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
7500000
CY2019Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1666000
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
22000
CY2019Q1 us-gaap Liabilities
Liabilities
12304000
CY2019Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q1 us-gaap Common Stock Value
CommonStockValue
25000
CY2019Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
174285000
CY2019Q1 us-gaap Treasury Stock Value
TreasuryStockValue
24000
CY2019Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-130204000
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24498275
CY2019Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24498425
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2316000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
44082000
CY2019Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
56386000
CY2019Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2019Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24528392
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24528242
CY2019Q1 us-gaap Treasury Stock Shares
TreasuryStockShares
29967
CY2018Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
29967
CY2019Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
653000
CY2019Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:GrantMember
CY2018Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:GrantMember
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5721000
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2235000
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
643000
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
8037000
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
2878000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7384000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2878000
CY2019Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
317000
CY2018Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
36000
CY2019Q1 us-gaap Interest Expense
InterestExpense
226000
CY2018Q1 us-gaap Interest Expense
InterestExpense
1404000
CY2018Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-5000
CY2018Q1 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-162000
CY2019Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
91000
CY2018Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1525000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-7293000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-4403000
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.30
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.90
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24498388
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
745812
CY2019Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
210000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
238000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock
AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
16000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
-101731000
CY2019Q1 us-gaap Profit Loss
ProfitLoss
-7293000
CY2018Q1 us-gaap Profit Loss
ProfitLoss
-4403000
CY2019Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
31000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-97416000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
104000
CY2018Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
27000
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
238000
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
104000
CY2019Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
129000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51914000
CY2018Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
1365000
CY2019Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
437000
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
99000
CY2019Q1 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
616000
CY2019Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
938000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61051000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13406000
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-246000
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
225000
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
129000
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1533000
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-257000
CY2019Q1 phas Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
8000
CY2018Q1 phas Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
-2000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8731000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2634000
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
84000
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6000
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-84000
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6000
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-322000
CY2019Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-9137000
CY2018Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2640000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10766000
CY2019Q1 us-gaap Interest Paid Net
InterestPaidNet
98000
CY2018Q1 us-gaap Interest Paid Net
InterestPaidNet
39000
CY2019Q1 phas Accrued Interest On Term Loan Refinanced To Principal
AccruedInterestOnTermLoanRefinancedToPrincipal
308000
CY2019Q1 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
209000
CY2019Q1 phas Debt Refinanced With New Term Loan
DebtRefinancedWithNewTermLoan
6563000
CY2019Q1 phas Initial Recognition Of Operating Lease Right Of Use Assets And Operating Lease Liabilities
InitialRecognitionOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilities
1991000
CY2018Q1 phas Accretion Of Redeemable Convertible Preferred Stock
AccretionOfRedeemableConvertiblePreferredStock
16000
CY2019Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
11000
CY2018Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
10000
CY2019Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s condensed financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s condensed financial statements and accompanying notes. The most significant estimates in the Company&#8217;s condensed financial statements relate to the valuation of redeemable convertible preferred stock warrants prior to the IPO, the conversion option on the convertible notes prior to conversion and clinical trial accruals. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results could differ materially from those estimates and assumptions.</p>
CY2019Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Concentrations of Credit Risk</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains certain deposit accounts and money market funds in federally insured financial institutions in excess of federally insured limits. The Company could experience losses on the money market funds in the future.</p>
CY2019Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
The Company effected a 11.0634-for-1 reverse split of its outstanding common stock and redeemable convertible preferred stock.
CY2019Q1 phas Working Capital
WorkingCapital
50300000
CY2019Q1 us-gaap Restricted Cash
RestrictedCash
20000
CY2018Q4 us-gaap Restricted Cash
RestrictedCash
20000
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2638258
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10692168
CY2019Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2196000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2140000
CY2019Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1816000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1785000
CY2019Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
447000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1358000
CY2019Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
401000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
914000
CY2019Q1 us-gaap Interest Payable Current
InterestPayableCurrent
10000
CY2018Q4 us-gaap Interest Payable Current
InterestPayableCurrent
194000
CY2019Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
262000
CY2019Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
196000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
305000
CY2019Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
2139000
CY2019Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
2285000
CY2019Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
2441000
CY2019Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
635000
CY2019Q1 us-gaap Long Term Debt
LongTermDebt
7500000
CY2019Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y8M12D
CY2019Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.064
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
254000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
372000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
377000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
363000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
272000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
776000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2414000
CY2019Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
486000
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
104000
CY2019Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1928000
CY2019Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000
CY2018Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
238000

Files In Submission

Name View Source Status
0001564590-19-017982-index-headers.html Edgar Link pending
0001564590-19-017982-index.html Edgar Link pending
0001564590-19-017982.txt Edgar Link pending
0001564590-19-017982-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
phas-10q_20190331.htm Edgar Link pending
phas-20190331.xml Edgar Link completed
phas-20190331.xsd Edgar Link pending
phas-20190331_cal.xml Edgar Link unprocessable
phas-20190331_def.xml Edgar Link unprocessable
phas-20190331_lab.xml Edgar Link unprocessable
phas-20190331_pre.xml Edgar Link unprocessable
phas-ex311_7.htm Edgar Link pending
phas-ex312_8.htm Edgar Link pending
phas-ex321_6.htm Edgar Link pending
phas-ex322_9.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending